

# Claudia Rossig

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6545529/publications.pdf>

Version: 2024-02-01

89  
papers

5,775  
citations

117625

34  
h-index

76900

74  
g-index

96  
all docs

96  
docs citations

96  
times ranked

6214  
citing authors

#	ARTICLE	IF	CITATIONS
1	Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. <i>Nature Medicine</i> , 2008, 14, 1264-1270.	30.7	1,063
2	Antitumor activity and long-term fate of chimeric antigen receptor <sup>+</sup> positive T cells in patients with neuroblastoma. <i>Blood</i> , 2011, 118, 6050-6056.	1.4	984
3	Adapting a transforming growth factor $\beta$ -related tumor protection strategy to enhance antitumor immunity. <i>Blood</i> , 2002, 99, 3179-3187.	1.4	310
4	Epstein-Barr virus <sup>+</sup> specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. <i>Blood</i> , 2002, 99, 2009-2016.	1.4	185
5	Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. <i>Leukemia</i> , 2006, 20, 1819-1828.	7.2	179
6	2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells. <i>Clinical Cancer Research</i> , 2009, 15, 4857-4866.	7.0	171
7	Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. <i>Leukemia</i> , 2019, 33, 884-892.	7.2	158
8	Targeting of GD2-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. <i>International Journal of Cancer</i> , 2001, 94, 228-236.	5.1	143
9	The ganglioside antigen GD2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. <i>British Journal of Cancer</i> , 2012, 106, 1123-1133.	6.4	112
10	Human $\gamma\delta$ T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. <i>British Journal of Haematology</i> , 2004, 126, 583-592.	2.5	103
11	Relapsed or Refractory Anaplastic Large-Cell Lymphoma in Children and Adolescents After Berlin-Frankfurt-Muenster (BFM) <sup>+</sup> Type First-Line Therapy: A BFM-Group Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 3065-3071.	1.6	101
12	Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. <i>Oncotarget</i> , 2017, 6, e1250050.	4.6	86
13	PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 317-320.	2.4	81
14	Genetic Modification of T Lymphocytes for Adoptive Immunotherapy. <i>Molecular Therapy</i> , 2004, 10, 5-18.	8.2	77
15	Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells. <i>Clinical Cancer Research</i> , 2017, 23, 3499-3509.	7.0	76
16	Effective childhood cancer treatment: The impact of large scale clinical trials in Germany and Austria. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1574-1581.	1.5	70
17	EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells. <i>Molecular Therapy</i> , 2019, 27, 933-946.	8.2	69
18	Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma. <i>Clinical Cancer Research</i> , 2015, 21, 4935-4946.	7.0	68

#	ARTICLE	IF	CITATIONS
19	Design and Characterization of an "All-in-One" Lentiviral Vector System Combining Constitutive Anti-GD2 CAR Expression and Inducible Cytokines. <i>Cancers</i> , 2020, 12, 375.	3.7	68
20	Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. <i>Blood Cancer Journal</i> , 2020, 10, 77.	6.2	65
21	Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia. <i>Leukemia</i> , 2017, 31, 1087-1095.	7.2	64
22	Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers. <i>Cancers</i> , 2020, 12, 1075.	3.7	57
23	NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR <sup>+</sup> ABL-positive mice. <i>Leukemia</i> , 2012, 26, 465-474.	7.2	56
24	Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia. <i>Leukemia</i> , 2016, 30, 970-973.	7.2	54
25	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 52-66.	2.8	52
26	A high proportion of bone marrow T cells with regulatory phenotype (CD4 <sup>+</sup> CD25 <sup>hi</sup> FoxP3 <sup>+</sup> ) in Ewing sarcoma patients is associated with metastatic disease. <i>International Journal of Cancer</i> , 2009, 125, 879-886.	5.1	51
27	Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1312-1321.	10.7	50
28	A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study). <i>Blood</i> , 2021, 137, 1582-1590.	1.4	48
29	Rhabdomyosarcoma Lysis by T Cells Expressing a Human Autoantibody-Based Chimeric Receptor Targeting the Fetal Acetylcholine Receptor. <i>Cancer Research</i> , 2006, 66, 24-28.	0.9	45
30	Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells. <i>Oncotarget</i> , 2017, 8, 108584-108603.	1.8	42
31	FUS <sup>+</sup> DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma. <i>Clinical Cancer Research</i> , 2017, 23, 6227-6238.	7.0	40
32	CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing. <i>BMC Cancer</i> , 2019, 19, 895.	2.6	40
33	Programmed cell death ligand 1 (PD <sup>L1</sup> ) expression is not a predominant feature in Ewing sarcomas. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26719.	1.5	39
34	2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1991-2001.	4.2	38
35	Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group. <i>Haematologica</i> , 2019, 104, 120-127.	3.5	38
36	T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G. <i>Oncotarget</i> , 2018, 9, 6536-6549.	1.8	37

#	ARTICLE	IF	CITATIONS
37	Activated human $\hat{I}^3\hat{I}$ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 385-396.	4.2	36
38	SS18-SSXâ€œDependent YAP/TAZ Signaling in Synovial Sarcoma. <i>Clinical Cancer Research</i> , 2019, 25, 3718-3731.	7.0	36
39	Activated Human $\hat{I}^3\hat{I}$ T Cells as Stimulators of Specific CD8+ T-cell Responses to Subdominant Epstein Barr Virus Epitopes. <i>Journal of Immunotherapy</i> , 2009, 32, 310-321.	2.4	34
40	Gene-Engineered Varicella-Zoster Virusâ€œReactive CD4+ Cytotoxic T Cells Exert Tumor-Specific Effector Function. <i>Cancer Research</i> , 2007, 67, 8335-8343.	0.9	30
41	Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies. <i>Gene Therapy</i> , 2016, 23, 615-626.	4.5	30
42	Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers. <i>Frontiers in Oncology</i> , 2018, 8, 513.	2.8	29
43	Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. <i>Blood Advances</i> , 2021, 5, 2901-2908.	5.2	29
44	Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 834-844.	4.1	28
45	Target Antigen Expression on a Professional Antigen-Presenting Cell Induces Superior Proliferative Antitumor T-Cell Responses via Chimeric T-Cell Receptors. <i>Journal of Immunotherapy</i> , 2006, 29, 21-31.	2.4	27
46	Aetiology of childhood acute leukaemias: current status of knowledge. <i>Radiation Protection Dosimetry</i> , 2008, 132, 114-118.	0.8	27
47	Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with $\hat{I}^3\hat{I}^2+$ $\hat{I}^3\hat{I}$ T cells. <i>Oncolmmunology</i> , 2016, 5, e1025194.	4.6	27
48	Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)â†. <i>ESMO Open</i> , 2021, 6, 100250.	4.5	27
49	Requirement for YAP1 signaling in myxoid liposarcoma. <i>EMBO Molecular Medicine</i> , 2019, 11, .	6.9	25
50	Comprehensive assessments and related interventions to enhance the long-term outcomes of child, adolescent and young adult cancer survivors â€œ presentation of the CARE for CAYA-Program study protocol and associated literature review. <i>BMC Cancer</i> , 2020, 20, 16.	2.6	25
51	Adoptive Cellular Immunotherapy with CD19-Specific T Cells. <i>Klinische Padiatrie</i> , 2005, 217, 351-356.	0.6	24
52	VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28313.	1.5	24
53	Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer. <i>European Journal of Cancer</i> , 2022, 160, 112-133.	2.8	24
54	Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging. <i>British Journal of Cancer</i> , 2013, 109, 658-666.	6.4	23

#	ARTICLE	IF	CITATIONS
55	Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial. <i>Leukemia</i> , 2022, 36, 1516-1524.	7.2	21
56	Anchorage-independent growth of Ewing sarcoma cells under serum-free conditions is not associated with stem-cell like phenotype and function. <i>Oncology Reports</i> , 2014, 32, 845-852.	2.6	20
57	GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18. <i>Frontiers in Immunology</i> , 2022, 13, 839783.	4.8	20
58	CAR T cell immunotherapy in hematology and beyond. <i>Clinical Immunology</i> , 2018, 186, 54-58.	3.2	19
59	Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1047-1060.	4.2	18
60	Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone. <i>Scientific Reports</i> , 2019, 9, 19704.	3.3	18
61	Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 186.	3.5	18
62	Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity. <i>Sarcoma</i> , 2016, 2016, 1-6.	1.3	16
63	CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells. <i>Clinical and Experimental Immunology</i> , 2006, 144, 447-457.	2.6	15
64	Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium. <i>European Journal of Cancer</i> , 2020, 141, 82-91.	2.8	15
65	High Proportions of CD4+ T Cells among Residual Bone Marrow T Cells in Childhood Acute Lymphoblastic Leukemia Are Associated with Favorable Early Responses. <i>Acta Haematologica</i> , 2014, 131, 28-36.	1.4	13
66	Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET $\geq 2$ ) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOHâ€HD2002 trial. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27539.	1.5	12
67	SIRPÎ±-specific monoclonal antibody enables antibody-dependent phagocytosis of neuroblastoma cells. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 71-83.	4.2	11
68	HLA-G and HLA-E Immune Checkpoints Are Widely Expressed in Ewing Sarcoma but Have Limited Functional Impact on the Effector Functions of Antigen-Specific CAR T Cells. <i>Cancers</i> , 2021, 13, 2857.	3.7	11
69	Generation of an NFÎ±B-Driven Alpharetroviral â€œAll-in-Oneâ€ Vector Construct as a Potent Tool for CAR NK Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 751138.	4.8	11
70	Selection of human antitumor single-chain Fv antibodies from the B-cell repertoire of patients immunized against autologous neuroblastoma. <i>Medical and Pediatric Oncology</i> , 2000, 35, 692-695.	1.0	10
71	Cellular immunotherapy strategies for Ewing sarcoma. <i>Immunotherapy</i> , 2014, 6, 611-621.	2.0	10
72	A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study. <i>Blood</i> , 2020, 136, 8-9.	1.4	10

#	ARTICLE	IF	CITATIONS
73	New Targets and Targeted Drugs for the Treatment of Cancer: An Outlook to Pediatric Oncology. <i>Pediatric Hematology and Oncology</i> , 2011, 28, 539-555.	0.8	9
74	Development of Curative Therapies for Ewing Sarcomas by Interdisciplinary Cooperative Groups in Europe. <i>Klinische Padiatrie</i> , 2015, 227, 108-115.	0.6	9
75	Calcitonin receptor-like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML. <i>Blood Advances</i> , 2021, 5, 4413-4421.	5.2	9
76	Extending the chimeric receptor-based T-cell targeting strategy to solid tumors. <i>Oncolmmunology</i> , 2013, 2, e26091.	4.6	8
77	Zoledronic acid negatively affects the expansion of in vitro activated human NK cells and their cytolytic interactions with Ewing sarcoma cells. <i>Oncology Reports</i> , 2013, 29, 2348-2354.	2.6	8
78	Research recommendations toward a better understanding of the causes of childhood leukemia. <i>Blood Cancer Journal</i> , 2011, 1, e1-e1.	6.2	6
79	Surface expression of the immunotherapeutic target $\text{CD}2$ in osteosarcoma depends on cell confluency. <i>Cancer Reports</i> , 2021, 4, e1394.	1.4	6
80	Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes. <i>Cancers</i> , 2021, 13, 5577.	3.7	5
81	Redirecting T cells to treat solid pediatric cancers. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 611-624.	5.9	3
82	The Cellular Tumor Immune Microenvironment of Childhood Solid Cancers: Informing More Effective Immunotherapies. <i>Cancers</i> , 2022, 14, 2177.	3.7	2
83	SS18-SSX drives CREB activation in synovial sarcoma. <i>Cellular Oncology (Dordrecht)</i> , 2022, 45, 399-413.	4.4	2
84	Sequential acquisition of IgH and TCR rearrangements during the preleukemic phase of acute lymphoblastic leukemia in an adolescent patient. <i>Pediatric Blood and Cancer</i> , 2011, 56, 301-303.	1.5	1
85	Immune modulation by molecular cancer targets and targeted therapies. <i>Oncolmmunology</i> , 2012, 1, 358-360.	4.6	1
86	T-Cells Redirected Against the kappa Light Chain of Human Immunoglobulins Target Mature B Cell Derived Malignancies In Vitro and In Vivo.. <i>Blood</i> , 2005, 106, 612-612.	1.4	1
87	Spezifische Immuntherapien zur Behandlung von Krebs im Kindesalter. <i>Monatsschrift Fur Kinderheilkunde</i> , 2003, 151, 646-653.	0.1	0
88	Expression of disialoganglioside GD2 and prognosis in breast cancer subtypes. <i>Senologie - Zeitschrift Für Mammadiagnostik Und -therapie</i> , 2021, 18, .	0.0	0
89	Functional Consequences of TCAB1 Mutations in Dyskeratosis Congenita. <i>Blood</i> , 2016, 128, 3890-3890.	1.4	0